Mladenović J, Borojević N, Cikarić S, Jelić Lj
Institute of Oncology and Radiology of Serbia, Belgrade.
Srp Arh Celok Lek. 2000 Sep-Oct;128(9-10):322-7.
Breast cancer is the most frequent cancer in elderly patients (over 65 years). The recent data indicate that in women aged over 72 years the incidence of breast cancer is twice greater than in women aged 45 years. As more and more women are getting older, the total incidence of breast cancer can be expected to increase. The treatment of these patients is complicated by many other diseases including cardiovascular and pulmonary disorders associated with aging, and because chemotherapy and radical surgery are often contraindicated.
In an one year period in the Institute of Oncology and Radiology of Serbia a group of 53 elderly (65 years and more) patients with locally advanced breast cancer were treated. Twenty four patients (group A) were treated with hypofractionated (concentrated) radiotherapy. The irradiation was delivered to the breast with TD24-26 Gy with two tangentional portals and 19 Gy to regional lymphatics with anterior fields owner 8 fractions, breast and lymphatics alternatively. The same treatment plan was repeated after 28 days (split course). Co60 was used. Twenty nine patients (group B) were treated with conventional fractionated radiotherapy. Irradiation was delivered to the breast with 51 Gy tumour dose in 16 fractions and to the lymphatics with 45 Gy in 15 fractions. Breast and lymphatics were irradiated alternatively, during 31 working days. After 51 Gy the whole breast was boosted with 20 Gy tumour dose and axilla with TD 12 Gy. The concentrated radiotherapy is, in fact, an alternative for radical--conventional or protracted radiotherapy according to the so-called hypofractionated split course technique. Both techniques have very similar TDF factors. The aim of such a plan is the achievement of adequate tumour dose adapted to the age of patients (the patients should be treated in a smaller number of fractions). All patients were aged 65 years or were older. The median age in group A was 72 years and in group B 68 years. Also in all patients breast cancer was locally advanced (stadium III). In group A median follow-up was 29.79 months and in group B 23.62 months.
All patients had acute skin reactions. In group A (irradiated with concentrated technique) 91.7% of patients had erythema, 8.3% dry desquamation, but moist desquamation was not observed. In group B (irradiated with conventional technique) 27.6% of patients had erythema, 55.2% dry desquamation and 17.2% moist desquamation. Delayed radiation changes manifested as fibrosis of the breast and region of axilla were noted in 29.24% of patients in group A and 13.8% in group B. The relapse in group A was 41.7% with median relapse free interval of 13.9 months and in group B 48.2% with relapse free interval of 15.6 months. There was no significant statistical difference between the two groups according to standard statistical methods (chi 2 = 0.96; DF = 3; p > 0.05). After approximately 30 months of follow-up, 50% of patients in group A are alive without signs of disease; 16.7% are alive with disease, and 16.7% are dead due to primary disease. In group B 24.1% of patients are alive without signs of disease; 24.1% are alive with disease; and 20.7% are dead due to primary disease. There was no significant statistical difference between the two groups (chi 2 = 4.09; DF = 4; p > 0.05). The overall survival rate in group A was 67% after 4 years and 53% in group B. Relapse free survival was 53% in group A after 4 years and 36% in group B. In conclusion, according to our study there was no statistically significant difference in local control between conventional and hypofractionated radiotherapy in the treatment in elderly patients. The main advantage of concentrated schedule is shortening of duration of irradiation, but the main disadvantage is a high incidence of fibrosis which makes difficult the evaluation of local control. Consensus about treatment of breast cancer in elderly women has not yet been clearly established. Our data suggest that hypofractionated schedule is an effective, suitable and comfortable therapeutic approach in the management of breast cancer in elderly women.
乳腺癌是老年患者(65岁以上)中最常见的癌症。最近的数据表明,72岁以上女性的乳腺癌发病率是45岁女性的两倍。随着越来越多的女性步入老年,乳腺癌的总发病率预计将会上升。这些患者的治疗因许多其他疾病而变得复杂,包括与衰老相关的心血管和肺部疾病,并且化疗和根治性手术通常是禁忌的。
在塞尔维亚肿瘤与放射研究所的一年时间里,对一组53例老年(65岁及以上)局部晚期乳腺癌患者进行了治疗。24例患者(A组)接受了超分割(集中)放疗。采用两个切线野对乳房进行24 - 26 Gy的照射剂量,用前野对区域淋巴结进行19 Gy的照射剂量,共8次分割,乳房和淋巴结交替照射。28天后重复相同的治疗计划(分割疗程)。使用钴60。29例患者(B组)接受了常规分割放疗。对乳房进行16次分割、肿瘤剂量为51 Gy的照射,对淋巴结进行15次分割、45 Gy的照射。乳房和淋巴结交替照射,持续31个工作日。在51 Gy之后,对整个乳房追加20 Gy的肿瘤剂量,对腋窝追加12 Gy的肿瘤剂量。实际上,根据所谓的超分割分割疗程技术,集中放疗是根治性——常规或延长放疗的一种替代方法。两种技术具有非常相似的TDF因子。这样一个计划的目的是实现适合患者年龄的足够肿瘤剂量(患者应在较少的分割次数下接受治疗)。所有患者年龄均在65岁或以上。A组患者的中位年龄为72岁,B组为68岁。所有患者的乳腺癌均为局部晚期(Ⅲ期)。A组的中位随访时间为29.79个月,B组为23.62个月。
所有患者均出现急性皮肤反应。在A组(采用集中技术照射)中,91.7%的患者出现红斑,8.3%出现干性脱皮,但未观察到湿性脱皮。在B组(采用常规技术照射)中,27.6%的患者出现红斑,55.2%出现干性脱皮,17.2%出现湿性脱皮。A组29.24%的患者和B组13.8%的患者出现了表现为乳房和腋窝区域纤维化的迟发性放射改变。A组的复发率为41.7%,无复发生存期的中位数为13.9个月;B组的复发率为48.2%,无复发生存期为15.6个月。根据标准统计方法,两组之间无显著统计学差异(卡方 = 0.96;自由度 = 3;p > 0.05)。经过大约30个月的随访,A组50%的患者存活且无疾病迹象;16.7%的患者存活但患有疾病,16.7%的患者因原发性疾病死亡。B组24.1%的患者存活且无疾病迹象;24.1%的患者存活但患有疾病;20.7%的患者因原发性疾病死亡。两组之间无显著统计学差异(卡方 = 4.09;自由度 = 4;p > 0.05)。4年后A组的总生存率为67%,B组为53%。4年后A组的无复发生存率为53%,B组为36%。总之,根据我们的研究,在老年患者的治疗中,常规放疗和超分割放疗在局部控制方面无统计学显著差异。集中放疗方案的主要优点是缩短了照射时间,但主要缺点是纤维化发生率高,这使得局部控制的评估变得困难。关于老年女性乳腺癌治疗的共识尚未明确确立。我们的数据表明,超分割放疗方案是老年女性乳腺癌管理中一种有效、合适且舒适的治疗方法。